Abstract
Background and aims Prostate cancer (PCa) is the most frequently diagnosed cancer in men in Norway and as survival rates improve cardiovascular disease (CVD) has emerged as a primary cause of morbidity and mortality, including acute myocardial infarction (AMI). Cancer and CVD share some important risk factors and PCa treatment may increase the risk of CVD. The aim of this study was to compare rates of invasive management, in-hospital complications, major adverse cardiovascular events (MACE), re-infarction and death, as well as prescription of guideline recommended secondary pharmacological prevention after an AMI between PCa patients and the general male AMI population.
Methods Data included nation-wide registry data to identify all males 40-85 years in Norway who had their first AMI during 2013-2019. We compared outcomes after AMI between those diagnosed with localized PCa between 2004-2019 and the general AMI population using logistic and cause-specific Cox regression.
Results 34,362 AMI patients were included, of whom 1405 (4.1%) had PCa. No differences were observed in invasive management or secondary medical treatment post-AMI between PCa patients and non-cancer patients. While PCa patients had a lower risk of overall complications (OR 0.77; 0.64-0.92), they experienced an increased risk of serious bleeding (OR 1.66; 1.08-2.44) and no difference in MACE or re-infarction events. PCa patients had better 1-year survival (HR 0.82; 0.69-0.98).
Conclusions There was no evidence of reduced quality of AMI care for PCa patients in Norway. These findings support treatment of AMI as usual for localized PCa patients, but with attention to increased bleeding risk.
What is known
Evidence from studies evaluating quality of care and outcomes of cancer patients after an acute myocardial infarction have found that those with cancer are more likely to receive poorer quality of care and have worse outcomes, compared to non-cancer patients.
Prostate cancer is one of the most frequently diagnosed cancers in men, and as survival rates improve, cardiovascular disease has emerged as a primary cause of morbidity and mortality, including acute myocardial infarction.
What the study adds
There was no evidence that non-metastatic prostate cancer patients receive reduced quality of care when they experienced an acute myocardial infarction or that they were at higher risk of adverse outcomes in the following year.
Overall, risk of in-hospital complications was lower in prostate cancer patients, except for serious bleeding, which was more likely.
Non-metastatic prostate cancer patients should receive usual treatment for a myocardial infarction but with individualized consideration of their higher risk of bleeding.
Non-standard abbreviations and acronyms ADT = androgen deprivation therapy; CCI = Charlson comorbidity index; NorPD = Norwegian Prescription Database; NORMI = Norwegian Myocardial Infarction Quality Registry PCa = prostate cancer
Competing Interest Statement
Øystein Karlstad reports participation in research projects funded by Novo Nordisk, Bristol Myers Squibb and LEO Pharma, all regulator-mandated phase IV studies, all with funds paid to his institution (no personal fees) and with no relation to the work reported in this paper. None of the remaining authors have a disclosure of a relationship with industry or conflict of interest.
Clinical Trial
n/a
Funding Statement
This work was supported by a grant from the Norwegian Cancer Society, Oslo Norway (grant number 208154) and with additional support from the Norwegian Institute of Public Health, Bergen, Norway
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Regional Committee for Medical Research South-East in Norway (130363).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The work was carried out at the Norwegian Institute of Public Health (Folkehelseinstituttet)
Data availability
The data underlying this article cannot be shared publicly because the linkages were performed and delivered under a data permit that does not allow publicly sharing of data for the privacy of individuals included. The datasets can be identified and applied for through https://helsedata.no or can be shared upon reasonable request to the corresponding author, and after appropriate ethical approval have been granted.
